Published on 11 May 2022 on Zacks via Yahoo Finance
Epizyme (EPZM) Q1 Earnings Miss, Revenues Lag Estimates
Epizyme, Inc. EPZM incurred a loss of 38 cents per share for first-quarter 2022, narrower than the year-ago period’s loss of 69 cents.
Adjusted loss (excluding gains on change in fair value of warrants to purchase common stock) for the first quarter was 39 cents, wider than the Zacks Consensus Estimate of a loss of 35 cents but narrower than the year-ago period’s loss of 69 cents.
Total revenues for the first quarter were $8.7 million, which missed the Zacks Consensus Estimate of $10.9 million but increased from the year-ago quarter’s $7.6 million.